MARKET

NTEC

NTEC

Intec Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.1874
+0.0054
+2.97%
After Hours: 0.1851 -0.0023 -1.23% 19:39 04/03 EDT
OPEN
0.2000
PREV CLOSE
0.1820
HIGH
0.2000
LOW
0.1800
VOLUME
549.48K
TURNOVER
--
52 WEEK HIGH
7.99
52 WEEK LOW
0.1324
MARKET CAP
4.89M
P/E (TTM)
-0.4554
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 3 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average NTEC stock price target is 0.3750 with a high estimate of 0.5000 and a low estimate of 0.2500.

EPS

NTEC News

More
  • The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment
  • Benzinga · 03/17 15:38
  • Intec Pharma EPS beats by $0.01
  • seekingalpha · 03/13 16:43
  • Intec Pharma Reports Fourth Quarter and Year End 2019 Financial Results and Corporate Update
  • PR Newswire · 03/13 12:30
  • Intec Pharma Q4 EPS $(0.19) Up From $(0.38) YoY
  • Benzinga · 03/13 11:31

Industry

Biotechnology & Medical Research
-0.51%
Pharmaceuticals & Medical Research
-0.22%

Hot Stocks

Symbol
Price
%Change

About NTEC

Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs. The Company is focusing on the clinical development program for the Phase III clinical study of the Accordion Pill Carbidopa Levodopa (AP-CDLD), for the treatment of advanced stages Parkinson’s disease patients. Its pipeline also comprises The Accordion Pill-Zaleplon, a drug for sleep onset, which is in Phase II clinical program. Furthermore under research is Accordion Pill-Undisclosed Drug for the prevention and treatment of small bowel non-steroidal anti-inflammatory drug (NSAID) induced ulcers.
More

Webull offers kinds of Intec Pharma Ltd stock information, including NASDAQ:NTEC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NTEC stock news, and many more online research tools to help you make informed decisions.